Comment by makomk

The risk is that even if that lower dose with a lower antibody response works fine with existing variants, it might not fare so well against future mutations. I think this has already happened to a certain extent with the currently circulating variants - vaccination programs that gave worse antibody responses fared OK against the original variant, but not so well against newer ones.